{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,8]],"date-time":"2026-02-08T07:57:37Z","timestamp":1770537457541,"version":"3.49.0"},"reference-count":166,"publisher":"IntechOpen","isbn-type":[{"value":"9781803560922","type":"print"},{"value":"9781803560939","type":"electronic"}],"license":[{"start":{"date-parts":[[2023,3,15]],"date-time":"2023-03-15T00:00:00Z","timestamp":1678838400000},"content-version":"unspecified","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/3.0\/legalcode"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"abstract":"<jats:p>Multiple myeloma (MM) is a monoclonal plasma cell neoplasia that commonly involves the kidney. Renal impairment is a serious complication during the course of the disease, and it is associated with increased morbidity and mortality. The most frequent mechanism of injury is represented by the precipitation of monoclonal free light chains (FLCs) in the distal tubule of nephron, defining a dramatic condition known as light chain cast nephropathy (LCCN). A prompt and early identification of the cause of renal disease, particularly in case of acute kidney injury (AKI), is mandatory for its effective management, avoiding the development of chronic kidney disease (CKD). In case of LCCN, in order to achieve renal recovery, it is needed, besides preventive measures, urgent intervention based on vigorous rehydration, correction of precipitating factors and effective anti-plasma cell chemotherapy. Currently, the association of the Proteasome Inhibitor Bortezomib with high-dose of Dexamethasone represents the standard association in newly diagnosed patients. The addition of another drug such as Cyclophosphamide or an Immunomodulatory Drugs may improve FLCs reduction but could be toxic. Interesting is the role of the newest therapeutic agents, particularly anti-CD38 Monoclonal Antibodies, whose efficacy and tolerance have been documented in patients without renal impairment. Despite controversial results from randomized studies, recent data suggest that in patients with LCCN and AKI requiring dialysis the association of systemic therapy with an extra-corporeal approach of FLCs removal, may increase renal response recovery rates. In this chapter, it is summarized physio-pathological basis of MM renal impairment, clinical manifestations, diagnostic procedures, and therapeutic management, included autologous stem cell transplantation.<\/jats:p>","DOI":"10.5772\/intechopen.105444","type":"book-chapter","created":{"date-parts":[[2022,6,24]],"date-time":"2022-06-24T11:19:53Z","timestamp":1656069593000},"source":"Crossref","is-referenced-by-count":1,"title":["Management of Renal Failure in Multiple Myeloma"],"prefix":"10.5772","author":[{"given":"Daniele","family":"Derudas","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Claudia","family":"Concu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"3774","published-online":{"date-parts":[[2023,3,15]]},"reference":[{"key":"ref=1","doi-asserted-by":"crossref","unstructured":"Padala SA, Barsouk A, Barsouk A, Rawla P, Vakiti A, Kolhe R, et al. Epidemiology, staging, and management of multiple myeloma. Medical Science. 2021;9:3.4","DOI":"10.3390\/medsci9010003"},{"key":"ref=2","doi-asserted-by":"crossref","unstructured":"van de Donk N, Pawlyn C, Yong KL. Multiple myeloma. Lancet. 2021;397(10272):410-427","DOI":"10.1016\/S0140-6736(21)00135-5"},{"key":"ref=3","doi-asserted-by":"crossref","unstructured":"Rajkumar SV, Dimopoulos MA, Palumbo A, Blade J, Merlini G, Mateos MV, et al. International Myeloma Working Group updated criteria for the diagnosis of multiple myeloma. Lancet Oncology. 2014;15:e538-e548","DOI":"10.1016\/S1470-2045(14)70442-5"},{"key":"ref=4","doi-asserted-by":"crossref","unstructured":"Dimopoulos MA, Sonneveld P, Leung N, Merlini G, Ludwig H, Kastritis E, et al. International Myeloma Working Group recommendations for the diagnosis and management of myeloma-related renal impairment. Journal of Clinical Oncology. 2016;34(13):1544-1557","DOI":"10.1200\/JCO.2015.65.0044"},{"key":"ref=5","doi-asserted-by":"crossref","unstructured":"Alexanian R, Barlogie B, Dixon D, et al. Renal failure in multiple myeloma. Pathogenesis and prognostic implications. Archives of Internal Medicine. 1990;150(8):1693-1695","DOI":"10.1001\/archinte.150.8.1693"},{"key":"ref=6","doi-asserted-by":"crossref","unstructured":"Khan R, Apewokin S, Grazziutti M, Yaccoby S, Epstein J, van Rhee F, et al. Renal insufficiency retains adverse prognostic implications despite renal function improvement following total therapy for newly diagnosed multiple myeloma. Leukemia. 2015;29(5):1195-1201","DOI":"10.1038\/leu.2015.15"},{"key":"ref=7","doi-asserted-by":"crossref","unstructured":"Hutchison CA, Batuman V, Behrens J, Bridoux F, Sirac C, Dispenzieri A, et al. The pathogenesis and diagnosis of acute kidney injury in multiple myeloma. Nature Reviews. Nephrology. 2011;8:43-51","DOI":"10.1038\/nrneph.2011.168"},{"key":"ref=8","doi-asserted-by":"crossref","unstructured":"Leung N, Bridoux F, Hutchison CA, Nasr SH, Cockwell P, Fermand JP, et al. Monoclonal gammopathy of renal significance: When MGUS is no longer undetermined or insignificant. Blood. 2012;120:4292-4295","DOI":"10.1182\/blood-2012-07-445304"},{"key":"ref=9","doi-asserted-by":"crossref","unstructured":"Fermand JP, Bridoux F, Dispenzieri A, Jaccard A, Kyle RA, Leung N, et al. Monoclonal gammopathy of clinical significance: A novel concept with therapeutic implications. Blood. 2018;132:1478-1485","DOI":"10.1182\/blood-2018-04-839480"},{"key":"ref=10","doi-asserted-by":"crossref","unstructured":"Bridoux F, Leung N, Belmouaz M, Royal V, Ronco P, Nasr SH, et al. Management of acute kidney injury in symptomatic multiple myeloma. Kidney International. 2021;99:570-580","DOI":"10.1016\/j.kint.2020.11.010"},{"key":"ref=11","doi-asserted-by":"crossref","unstructured":"Sathick IJ, Drosou ME, Leung N. Myeloma light chain cast nephropathy, a review. Journal of Nephrology. 2019;32:189-198","DOI":"10.1007\/s40620-018-0492-4"},{"key":"ref=12","doi-asserted-by":"crossref","unstructured":"Blad\u00e8 J, Fern\u00e1ndez-Llama P, Bosch F, Montol\u00edu J, Lens XM, Montoto S, et al. Renal failure in multiple myeloma: Presenting features and predictors of outcome in 94 patients from a single institution. Archives of Internal Medicine. 1998;158:1889","DOI":"10.1001\/archinte.158.17.1889"},{"key":"ref=13","unstructured":"Kyle RA. Multiple myeloma: Review of 869 cases. Mayo Clinic Proceedings. 1975;50:29"},{"key":"ref=14","doi-asserted-by":"crossref","unstructured":"Kyle RA, Gertz MA, Witzig TE, Lust JA, Lacy MQ, Dispenzieri A, et al. Review of 1027 patients with newly diagnosed multiple myeloma. Mayo Clinic Proceedings. 2003;78:21","DOI":"10.4065\/78.1.21"},{"key":"ref=15","doi-asserted-by":"crossref","unstructured":"Knudsen LM, Hippe E, Hjorth M, Holmberg E, Westin J. Renal function in newly diagnosed multiple myeloma\u2014A demographic study of 1353 patients. The Nordic Myeloma Study Group. European Journal of Haematology. 1994;53:207","DOI":"10.1111\/j.1600-0609.1994.tb00190.x"},{"key":"ref=16","doi-asserted-by":"crossref","unstructured":"Torra R, Blad\u00e9 J, Cases A, L\u00f3pez-Pedret J, Montserrat E, Rozman C, et al. Patients with multiple myeloma requiring long-term dialysis: Presenting features, response to therapy, and outcome in a series of 20 cases. British Journal of Haematology. 1995;91:854","DOI":"10.1111\/j.1365-2141.1995.tb05400.x"},{"key":"ref=17","doi-asserted-by":"crossref","unstructured":"Knudsen LM, Hjorth M, Hippe E. Renal failure in multiple myeloma: Reversibility and impact on the prognosis. Nordic Myeloma Study Group. European Journal of Haematology. 2000;65:175","DOI":"10.1034\/j.1600-0609.2000.90221.x"},{"key":"ref=18","doi-asserted-by":"crossref","unstructured":"Johnson WJ, Kyle EA, Pineda AA, O\u2019Brien PC, Holley KE. Treatment of renal failure associated with multiple myeloma. Plasmapheresis, hemodialysis, and chemotherapy. Archives of Internal Medicine. 1990;150:863","DOI":"10.1001\/archinte.1990.00390160111022"},{"key":"ref=19","doi-asserted-by":"crossref","unstructured":"Terpos E, Christoulas D, Kastritis E, Katodritou E, Pouli A, Michalis E. Epidemiology Collaboration cystatin C (CKD-EPI-CysC) equation has an independent prognostic value for overall survival in newly diagnosed patients with symptomatic multiple myeloma; is it time to change from MDRD to CKD-EPI-CysC equations? European Journal of Haematology. 2013;91:347-355","DOI":"10.1111\/ejh.12164"},{"key":"ref=20","doi-asserted-by":"crossref","unstructured":"Gonsalves WI, Leung N, Rajkumar SV, Dispenzieri A, Lacy MQ, Hayman SR, et al. Improvement in renal function and its impact on survival in patients with newly diagnosed multiple myeloma. Blood Cancer Journal. 2015;5:e296","DOI":"10.1038\/bcj.2015.20"},{"key":"ref=21","doi-asserted-by":"crossref","unstructured":"Shi H, Zhang W, Li X, Ren H, Pan X, Chen N. Application of RIFLE criteria in patients with multiple myeloma with acute kidney injury: A 15-year retrospective, single center, cohort study. Leukemia & Lymphoma. 2014;55:1076-1082","DOI":"10.3109\/10428194.2013.820284"},{"key":"ref=22","doi-asserted-by":"crossref","unstructured":"Leung N, Nasr SH. Myeloma-related kidney disease. Advances in Chronic Kidney Disease. 2014;21(1):36-47","DOI":"10.1053\/j.ackd.2013.08.009"},{"key":"ref=23","unstructured":"Ivanyi B. Frequency of light chain deposition nephropathy relative to renal amyloidosis and Bence Jones cast nephropathy in a necropsy study of patients with myeloma. Archives of Pathology & Laboratory Medicine. 1990;114(9):986-987"},{"key":"ref=24","unstructured":"Pasquali S, Zucchelli P, Casanova S, Cagnoli L, Confalonieri R, Pozzi C, et al. Renal Immunopathology Group. Renal histological lesions and clinical syndromes in multiple myeloma. Clinical Nephrology. 1987;27(5):222-228"},{"key":"ref=25","doi-asserted-by":"crossref","unstructured":"Big\u00e8 N, Arnulf B, Hummel A, De Keyser E, Royal R, Buzyn A, et al. Urinary tract obstruction due to extramedullary plasmacytoma: Report of two cases. NDT Plus. 2009;2:143-146","DOI":"10.1093\/ndtplus\/sfn212"},{"key":"ref=26","doi-asserted-by":"crossref","unstructured":"Bridoux F, Carron PL, Pegourie B, Alamartine E, Augeul-Meunier K, Karras A, et al. Effect of high-cutoff hemodialysis vs conventional hemodialysis on hemodialysis independence among patients with myeloma cast nephropathy: A randomized clinical trial. Journal of the American Medical Association. 2017;318:2099-2110","DOI":"10.1001\/jama.2017.17924"},{"key":"ref=27","doi-asserted-by":"crossref","unstructured":"Bridoux F, Arnulf B, Karlin L, Blin N, Rabot N, Macro M, et al. Randomized trial comparing double versus triple bortezomib-based regimen in patients with multiple myeloma and acute kidney injury due to cast nephropathy. Journal of Clinical Oncology. 2020;38:2647-2657","DOI":"10.1200\/JCO.20.00298"},{"key":"ref=28","doi-asserted-by":"crossref","unstructured":"Blimark CH, Turesson I, Genell A, Ahlberg L, Bj\u00f6rkstrand B, Carlson K, et al. Outcome and survival of myeloma patients diagnosed 2008-2015: Real-world data on 4904 patients from the Swedish Myeloma Registry. Haematologica. 2018;103:506-513","DOI":"10.3324\/haematol.2017.178103"},{"key":"ref=29","doi-asserted-by":"crossref","unstructured":"Eleftherakis-Papapiakovou E, Kastritis E, Roussou M, Gkotzamanidou M, Grapsa I, Psimenou E, et al. Renal impairment is not an independent adverse prognostic factor in patient with multiple myeloma treated upfront with novel agent-based regimens. Leukemia & Lymphoma. 2011;52:2299-2303","DOI":"10.3109\/10428194.2011.597906"},{"key":"ref=30","doi-asserted-by":"crossref","unstructured":"Rota S, Mougenot B, Baudouin B, De Meyer-Brasseur M, Lemaitre V, Michel C, et al. Multiple myeloma and severe renal failure: A clinicopathologic study of outcome and prognosis in 34 patients. Medicine (Baltimore). 1987;66:126-137","DOI":"10.1097\/00005792-198703000-00004"},{"key":"ref=31","doi-asserted-by":"crossref","unstructured":"Blimark C, Holmberg E, Mellqvist UH, Landgren O, Bjorkholm M, Hultcrantz M, et al. Multiple myeloma and infections: A population-based study on 9253 multiple myeloma patients. Haematologica. 2015;100:107-113","DOI":"10.3324\/haematol.2014.107714"},{"key":"ref=32","doi-asserted-by":"crossref","unstructured":"Rabb H, Gunasekaran H, Gunasekaran S, Saba R, et al. Acute renal failure from multiple myeloma precipitated by ACE inhibitors. American Journal of Kidney Diseases. 1999;33:E5","DOI":"10.1016\/S0272-6386(99)70326-4"},{"key":"ref=33","doi-asserted-by":"crossref","unstructured":"Nasr SH, Valeri AM, Sethi S, Fidler ME, Cornell LD, Gertz MA, et al. Clinicopathologic correlations in multiple myeloma: A case series of 190 patients with kidney biopsies. American Journal of Kidney Diseases. 2012;59:786-794","DOI":"10.1053\/j.ajkd.2011.12.028"},{"key":"ref=34","doi-asserted-by":"crossref","unstructured":"Augustson BM, Begum G, Dunn JA, Barth NJ, Davies F, Morgan G, et al. Early mortality after diagnosis of multiple myeloma: Analysis of patients entered onto the United kingdom Medical Research Council trials between 1980 and 2002\u2013Medical Research Council Adult Leukaemia Working Party. Journal of Clinical Oncology. 2005;23(36):9219-9226","DOI":"10.1200\/JCO.2005.03.2086"},{"key":"ref=35","doi-asserted-by":"crossref","unstructured":"Weide R, Koppler H, Antras L, Smith M, Chang MPHE, Green J, et al. Renal toxicity in patients with multiple myeloma receiving zoledronic acid vs. ibandronate: A retrospective medical records review. Journal of Cancer Research and Therapeutics. 2010;6:31-35","DOI":"10.4103\/0973-1482.63570"},{"key":"ref=36","doi-asserted-by":"crossref","unstructured":"Ravindran A, Go RS, Fervenza FC, Sethi S. Thrombotic microangiopathy associated with monoclonal gammopathy. Kidney International. 2017;91:691-698","DOI":"10.1016\/j.kint.2016.09.045"},{"key":"ref=37","doi-asserted-by":"crossref","unstructured":"Lodhi A, Kumar A, Saqlain MU, Suneja M, et al. Thrombotic microangiopathy associated with proteasome inhibitors. Clinical Kidney Journal. 2015;8:632-636","DOI":"10.1093\/ckj\/sfv059"},{"key":"ref=38","doi-asserted-by":"crossref","unstructured":"Wesner N, Bihan K, Cez A, Simon L, Biour M, Ross-Weil D, et al. Two cases of reversible Fanconi syndrome induced by lenalidomide. Leukemia & Lymphoma. 2019;60:1092-1094","DOI":"10.1080\/10428194.2018.1515941"},{"key":"ref=39","doi-asserted-by":"crossref","unstructured":"Lipson EJ, Huff CA, Holanda DG, McDevitt MA, Fine DM, et al. Lenalidomide-induced acute interstitial nephritis. The Oncologist. 2010;15:961-964","DOI":"10.1634\/theoncologist.2010-0070"},{"key":"ref=40","doi-asserted-by":"crossref","unstructured":"Oiwa K, Morita M, Kishi S, Okura M, Tasaki T, Matsuda Y, et al. High risk of tumor lysis syndrome in symptomatic patients with multiple myeloma with renal dysfunction treated with bortezomib. Anticancer Research. 2016;36:6655-6662","DOI":"10.21873\/anticanres.11274"},{"key":"ref=41","unstructured":"Sanders J, P.W. Pathogenesis and treatment of myeloma kidney. The Journal of Laboratory and Clinical Medicine. 1994;124:484"},{"key":"ref=42","doi-asserted-by":"crossref","unstructured":"Buxbaum JN, Chuba JV, Hellman GC, Solomon A, Gallo GR. Clinical features, immunopathology, and molecular analysis. Monoclonal immunoglobulin deposition disease: Light chain and light and heavy chain deposition diseases and their relation to light chain amyloidosis. Annals of Internal Medicine. 1990;112:455","DOI":"10.7326\/0003-4819-76-3-112-6-455"},{"key":"ref=43","doi-asserted-by":"crossref","unstructured":"Ganeval D, Noel LH, Preud\u2019Homme JL, Droz D, Grunfeld JP, et al. Light-chain deposition disease: Its relation with AL-type amyloidosis. Kidney International. 1984;26:1","DOI":"10.1038\/ki.1984.126"},{"key":"ref=44","unstructured":"Kyle RA, Gertz MA. Primary systemic amyloidosis: Clinical and laboratory features in 474 cases. Seminars in Hematology. 1995;32:45"},{"key":"ref=45","doi-asserted-by":"crossref","unstructured":"Pozzi C, D\u2019Amico M, Fogazzi GB, Curioni S, Ferrario F, Pasquali S, et al. Light chain deposition disease with renal involvement: Clinical characteristics and prognostic factors. American Journal of Kidney Diseases. 2003;42:1154","DOI":"10.1053\/j.ajkd.2003.08.040"},{"key":"ref=46","doi-asserted-by":"crossref","unstructured":"Cogn\u00e9 M, Preud\u2019Homme JL, Bauwens M, Touchard G, Aucouturier P. Structure of a monoclonal kappa chain of the V kappa IV subgroup in the kidney and plasma cells in light chain deposition disease. The Journal of Clinical Investigation. 1991;87:2186","DOI":"10.1172\/JCI115252"},{"key":"ref=47","doi-asserted-by":"crossref","unstructured":"Vidal R, Goni F, Stevens F, Aucouturier P, Kumar A, Frangione B, et al. Somatic mutations of the L12a gene in V-kappa(1) light chain deposition disease: Potential effects on aberrant protein conformation and deposition. The American Journal of Pathology. 1999;155:2009","DOI":"10.1016\/S0002-9440(10)65520-4"},{"key":"ref=48","doi-asserted-by":"crossref","unstructured":"Solomon A. Light chains of human immunoglobulins. Methods in Enzymology. 1985;116:101-121","DOI":"10.1016\/S0076-6879(85)16008-8"},{"key":"ref=49","doi-asserted-by":"crossref","unstructured":"Li M, Balamuthusamy S, Simon EE, Batuman V. Silencing megalin and cubilin genes inhibits myeloma light chain endocytosis and ameliorates toxicity in human renal proximal tubule epithelial cells. American Journal of Physiology. Renal Physiology. 2008;295:F82-F90","DOI":"10.1152\/ajprenal.00091.2008"},{"key":"ref=50","doi-asserted-by":"crossref","unstructured":"Sanders PW. Mechanisms of light chain injury along the tubular nephron. Journal of the American Society of Nephrology. 2012;23:1777-1781","DOI":"10.1681\/ASN.2012040388"},{"key":"ref=51","doi-asserted-by":"crossref","unstructured":"Batuman V, Verroust PJ, Navar GL, Kaysen JH, Goda FO, Campbell WC, et al. Myeloma light chains are ligands for cubilin (gp280). The American Journal of Physiology. 1998;275:F246-F254","DOI":"10.1152\/ajprenal.1998.275.2.F246"},{"key":"ref=52","doi-asserted-by":"crossref","unstructured":"Christensen EI, Birn H, Storm T, Weyer K, Nielsen R. Endocytic receptors in the renal proximal tubule. Physiology (Bethesda, Md.). 2012;27:223-236","DOI":"10.1152\/physiol.00022.2012"},{"key":"ref=53","doi-asserted-by":"crossref","unstructured":"Sanders PW, Herrera GA, Galla JH, et al. Human Bence Jones protein toxicity in rat proximal tubule epithelium in vivo. Kidney International. 1987;32:851-861","DOI":"10.1038\/ki.1987.286"},{"key":"ref=54","doi-asserted-by":"crossref","unstructured":"Huang ZQ, Sanders PW. Localization of a single binding site for immunoglobulin light chains on human Tamm-Horsfall glycoprotein. The Journal of Clinical Investigation. 1997;99:732-736","DOI":"10.1172\/JCI119218"},{"key":"ref=55","doi-asserted-by":"crossref","unstructured":"Ying WZ, Sanders PW. Mapping the binding domain of immunoglobulin light chains for Tamm-Horsfall protein. The American Journal of Pathology. 2001;58:1859-1866","DOI":"10.1016\/S0002-9440(10)64142-9"},{"key":"ref=56","doi-asserted-by":"crossref","unstructured":"Royal V, Leng N, Troyanov S, Nasr SH, Ecotiere L, LeBlanc R, et al. Clinicopathologic predictors of renal outcomes in light chain cast nephropathy: A multicenter retrospective study. Blood. 2020;135:1833-1846","DOI":"10.1182\/blood.2019003807"},{"key":"ref=57","doi-asserted-by":"crossref","unstructured":"Sanders PW, Booker BB, Bishop JB, Cheung HC, et al. Mechanisms of intranephronal proteinaceous cast formation by low molecular weight proteins. The Journal of Clinical Investigation. 1990;85:570","DOI":"10.1172\/JCI114474"},{"key":"ref=58","doi-asserted-by":"crossref","unstructured":"Holland MD, Galla JH, Sanders PW, Luke RG. Effect of urinary pH and diatrizoate on Bence Jones protein nephrotoxicity in the rat. Kidney International. 1985;27:46","DOI":"10.1038\/ki.1985.8"},{"key":"ref=59","doi-asserted-by":"crossref","unstructured":"Sandres PW, Herrera GA, Chen A, Booker BB, Galla JH. Differential nephrotoxicity of low molecular weight proteins including Bence Jones proteins in the perfused rat nephron in vivo. The Journal of Clinical Investigation. 1988;82:2086","DOI":"10.1172\/JCI113830"},{"key":"ref=60","doi-asserted-by":"crossref","unstructured":"Weiss JH, Williams RH, Galla JH, Gottschall JL, Rees ED, Bhathena D, et al. Pathophysiology of acute Bence-Jones protein nephrotoxicity in the rat. Kidney International. 1981;20:198-210","DOI":"10.1038\/ki.1981.122"},{"key":"ref=61","doi-asserted-by":"crossref","unstructured":"Smolens P, Venkatachalam M, Stein JH. Myeloma kidney cast nephropathy in a rat model of multiple myeloma. Kidney International. 1983;24:192-204","DOI":"10.1038\/ki.1983.144"},{"key":"ref=62","doi-asserted-by":"crossref","unstructured":"Mulay SR, Anders HJ. Crystal nephropathies: Mechanisms of crystal-induced kidney injury. Nature Reviews. Nephrology. 2017;13:226-240","DOI":"10.1038\/nrneph.2017.10"},{"key":"ref=63","doi-asserted-by":"crossref","unstructured":"Sanders PW, Booker BB. Pathobiology of cast nephropathy from human Bence Jones proteins. The Journal of Clinical Investigation. 1992;89:630","DOI":"10.1172\/JCI115629"},{"key":"ref=64","unstructured":"Smolens P, Barnes JL, Kreisberg R. Hypercalcemia can potentiate the nephrotoxicity of Bence Jones proteins. The Journal of Laboratory and Clinical Medicine. 1987;110:460"},{"key":"ref=65","doi-asserted-by":"crossref","unstructured":"Morgan C Jr, Hammack WJ. Intravenous urography in multiple myeloma. The New England Journal of Medicine. 1966;275:77","DOI":"10.1056\/NEJM196607142750205"},{"key":"ref=66","doi-asserted-by":"crossref","unstructured":"Sakhuja V, Jha V, Varma S, Joshi K, Gupta KL, Sud K, et al. Renal involvement in multiple myeloma: A 10-year study. Renal Failure. 2000;22:465","DOI":"10.1081\/JDI-100100888"},{"key":"ref=67","doi-asserted-by":"crossref","unstructured":"Sengul S, Zwizinski C, Batuman V. Role of MAPK pathways in light chain-induced cytokine production in human proximal tubule cells. American Journal of Physiology. Renal Physiology. 2003;284:F1245-F1254","DOI":"10.1152\/ajprenal.00350.2002"},{"key":"ref=68","doi-asserted-by":"crossref","unstructured":"Wang PX, Sanders PW. Immunoglobulin light chains generate hydrogen peroxide. Journal of the American Society of Nephrology. 2007;18:1239-1245","DOI":"10.1681\/ASN.2006111299"},{"key":"ref=69","doi-asserted-by":"crossref","unstructured":"Ying WZ, Wang PX, Sanders PW. Pivotal role of apoptosis signal-regulating kinase 1 in monoclonal free light chain-mediated apoptosis. The American Journal of Pathology. 2012;180:41-47","DOI":"10.1016\/j.ajpath.2011.09.017"},{"key":"ref=70","doi-asserted-by":"crossref","unstructured":"Ying WZ, Li X, Rangarajan S, Feng W, Curtis LM, Sanders PW. Immunoglobulin light chains generate proinflammatory and profibrotic kidney injury. The Journal of Clinical Investigation. 2019;129:2792-2806","DOI":"10.1172\/JCI125517"},{"key":"ref=71","doi-asserted-by":"crossref","unstructured":"Yadav P, Sathick IJ, Leung N, Brown EE, Cook M, Sanders PW, et al. Serum free light chain level at diagnosis in myeloma cast nephropathy\u2014A multicentre study. Blood Cancer Journal. 2020;10:28","DOI":"10.1038\/s41408-020-0295-4"},{"key":"ref=72","doi-asserted-by":"crossref","unstructured":"Ying WZ, Allen CE, Curtis LM, Aaron KJ, Sanders PW. Mechanism and prevention of acute kidney injury from cast nephropathy in a rodent model. The Journal of Clinical Investigation. 2012;122:1777-1785","DOI":"10.1172\/JCI46490"},{"key":"ref=73","doi-asserted-by":"crossref","unstructured":"Masson I, Flamant M, Maillard N, Rule AD, Vrtovsnik F, Peraldi MN, et al. MDRD versus CKD-EPI equation to estimate glomerular filtration rate in kidney transplant recipients. Transplantation. 2013;95:1211-1217","DOI":"10.1097\/TP.0b013e318288caa6"},{"key":"ref=74","doi-asserted-by":"crossref","unstructured":"Levey AS, Eckardt KU, Tsukamoto Y, Levin A, Coresh J, Rossert J, et al. Definition and classification of chronic kidney disease: A position statement from Kidney Disease: Improving Global Outcomes (KDIGO). Kidney International. 2005;67:2089-2100","DOI":"10.1111\/j.1523-1755.2005.00365.x"},{"key":"ref=75","doi-asserted-by":"crossref","unstructured":"Michels WM, Grootendorst DC, Verduijn M, Elliot EG, Dekker FW, Krediet RT. Performance of the Cockcroft-Gault, MDRD, and new CKD-EPI formulas in relation to GFR, age, and body size. Clinical Journal of the American Society of Nephrology. 2010;5:1003-1009","DOI":"10.2215\/CJN.06870909"},{"key":"ref=76","doi-asserted-by":"crossref","unstructured":"Dimopoulos MA, Terpos E, Symeonidis AS, Katodritou E, Pouli A, Delimpasi S, et al. Estimated glomerular filtration rate calculated by the CKD-EPI formula has improved prognostic ability over MDRD formula in patients with newly diagnosed, symptomatic, multiple myeloma: Analysis in 1937 patients. Blood. 1867;122:2013 (abstr)","DOI":"10.1182\/blood.V122.21.1867.1867"},{"key":"ref=77","doi-asserted-by":"crossref","unstructured":"Terpos E, Christoulas D, Kastritis E, Katodritou E, Pouli A, Michalis E, et al. The Chronic Kidney Disease Epidemiology Collaboration cystatin C (CKD-EPI-CysC) equation has an independent prognostic value for overall survival in newly diagnosed patients with symptomatic multiple myeloma; is it time to change from MDRD to CKD-EPI-CysC equations? European Journal of Haematology. 2013;91:347-355","DOI":"10.1111\/ejh.12164"},{"key":"ref=78","doi-asserted-by":"crossref","unstructured":"Terpos E, Katodritou E, Tsiftsakis E, Kastritis E, Christoulas D, Pouli A, et al. Cystatin-C is an independent prognostic factor for survival in multiple myeloma and is reduced by bortezomib administration. Haematologica. 2009;94:372-379","DOI":"10.3324\/haematol.2008.000638"},{"key":"ref=79","doi-asserted-by":"crossref","unstructured":"Palumbo A, Avet-Loiseau H, Oliva S, Lokhorst HM, Goldschmidt H, Rosinol L, et al. Revised international staging system for multiple myeloma: A report from International Myeloma Working Group. Journal of Clinical Oncology. 2015;33:2863-2869","DOI":"10.1200\/JCO.2015.61.2267"},{"key":"ref=80","doi-asserted-by":"crossref","unstructured":"Srisawat N, Hoste EEA, Kellum JA. Modern classification of acute kidney injury. Blood Purification. 2010;29:300-307","DOI":"10.1159\/000280099"},{"key":"ref=81","doi-asserted-by":"crossref","unstructured":"Ando M, Mori J, Ohashi K, Akiyama H, Morito T, Tsuchiya K, et al. A comparative assessment of the RIFLE, AKIN and conventional criteria for acute kidney injury after hematopoietic SCT. Bone Marrow Transplantation. 2010;45:1427-1434","DOI":"10.1038\/bmt.2009.377"},{"key":"ref=82","doi-asserted-by":"crossref","unstructured":"Merlini G, Palladini G. Differential diagnosis of monoclonal gammopathy of undetermined significance. Hematology. American Society of Hematology. Education Program. 2012;2012:595-603","DOI":"10.1182\/asheducation.V2012.1.595.3798563"},{"key":"ref=83","doi-asserted-by":"crossref","unstructured":"Ecoti\u00e8re L, Thierry A, Debiais-Delpech C, Chevret S, Javaugue V, Desport E, et al. Prognostic value of kidney biopsy in myeloma cast nephropathy: A retrospective study of 70 patients. Nephrology, Dialysis, Transplantation. 2016;31:64-72","DOI":"10.1093\/ndt\/gfv283"},{"key":"ref=84","doi-asserted-by":"crossref","unstructured":"Vignon M, Javaugue V, Alexander MP, El-Karoui K, Karras A, Roos-Weil D, et al. Current anti-myeloma therapies in renal manifestations of monoclonal light chain-associated Fanconi syndrome: A retrospective series of 49 patients. Leukemia. 2017;31:123","DOI":"10.1038\/leu.2016.195"},{"key":"ref=85","doi-asserted-by":"crossref","unstructured":"Leung N, Behrens J. Current approach to diagnosis and management of acute renal failure in myeloma patients. Advances in Chronic Kidney Disease. 2012;19:297-302","DOI":"10.1053\/j.ackd.2012.06.001"},{"key":"ref=86","doi-asserted-by":"crossref","unstructured":"Bridoux F, Leung N, Belmouaz M, Royal V, Ronco P, Nasr SH, et al. Management of AKI in myeloma. Kidney International. 2021;99:570-580","DOI":"10.1016\/j.kint.2020.11.010"},{"key":"ref=87","doi-asserted-by":"crossref","unstructured":"Heher EC, Rennke HG, Laubach JP, Richardson PG. Kidney disease and multiple myeloma. Clinical Journal of the American Society of Nephrology. 2013;8:2007-2017","DOI":"10.2215\/CJN.12231212"},{"key":"ref=88","doi-asserted-by":"crossref","unstructured":"Raje N, Terpos E, Willenbacher W, Shimizu K, Garcia-Sanza R, Durie B, et al. Denosumab versus zoledronic acid in bone disease treatment of newly diagnosed multiple myeloma: An international, double-blind, double-dummy, randomised, controlled, phase 3 study. The Lancet Oncology. 2018;19:370-381","DOI":"10.1016\/S1470-2045(18)30072-X"},{"key":"ref=89","doi-asserted-by":"crossref","unstructured":"Leung N, Gertz MA, Zeldenrust SR, Rajkumar SV, Dispenzieri A, Fervenza FC, et al. Improvement of cast nephropathy with plasma exchange depends on the diagnosis and on reduction of serum free light chains. Kidney International. 2008;73:1282-1288","DOI":"10.1038\/ki.2008.108"},{"key":"ref=90","doi-asserted-by":"crossref","unstructured":"Hutchison CA, Cockwell P, Stringer S, Bradwell A, Cook M, Gertz MA, et al. Early reduction of serum-free light chains associates with renal recovery in myeloma kidney. Journal of the American Society of Nephrology. 2011;22:1129-1136","DOI":"10.1681\/ASN.2010080857"},{"key":"ref=91","doi-asserted-by":"crossref","unstructured":"Bayraktar UD, Warsch S, Pereira D. High-dose glucocorticoids improve renal failure reversibility in patients with newly diagnosed multiple myeloma. American Journal of Hematology. 2011;86:224-227","DOI":"10.1002\/ajh.21922"},{"key":"ref=92","doi-asserted-by":"crossref","unstructured":"Dimopoulos MA, Roussou M, Gkotzamanidou M, Nikitas N, Psimenou E, Mparmparoussi D, et al. The role of novel agents on the reversibility of renal impairment in newly diagnosed symptomatic patients with multiple myeloma. Leukemia. 2013;27:423-429","DOI":"10.1038\/leu.2012.182"},{"key":"ref=93","doi-asserted-by":"crossref","unstructured":"Chanan-Khan AA, San Miguel JF, Jagannath S, Ludwig H, Dimopoulos MA. Novel therapeutic agents for the management of patients with multiple myeloma and renal impairment. Clinical Cancer Research. 2012;18:2145-2163","DOI":"10.1158\/1078-0432.CCR-11-0498"},{"key":"ref=94","doi-asserted-by":"crossref","unstructured":"Ludwig H, Drach J, Graf H, Lang A, Gobertus MJ. Reversal of acute renal failure by bortezomib-based chemotherapy in patients with multiple myeloma. Haematologica. 2007;92:1411-1414","DOI":"10.3324\/haematol.11463"},{"key":"ref=95","doi-asserted-by":"crossref","unstructured":"Sonneveld P, Schmidt-Wolf IGH, van der Holt B, El Jarari L, Bertsch U, Salwender H, et al. Bortezomib induction and maintenance treatment in patients with newly diagnosed multiple myeloma: Results of the randomized phase III HOVON-65\/GMMG-HD4 trial. Journal of Clinical Oncology. 2012;30:2946-2955","DOI":"10.1200\/JCO.2011.39.6820"},{"key":"ref=96","doi-asserted-by":"crossref","unstructured":"San-Miguel JF, Richardson PG, Sonneveld P, Schuster MW, Irwin D, Stadtmauer EA, et al. Efficacy and safety of bortezomib in patients with renal impairment: Results from the APEX phase 3 study. Leukemia. 2008;22:842-849","DOI":"10.1038\/sj.leu.2405087"},{"key":"ref=97","doi-asserted-by":"crossref","unstructured":"Manasanch EE, Orlowski RZ. Proteasome inhibitors in cancer therapy. Nature Reviews. Clinical Oncology. 2017;14:417-433","DOI":"10.1038\/nrclinonc.2016.206"},{"key":"ref=98","doi-asserted-by":"crossref","unstructured":"Badros AZ, ViJ R, Martin T, Zonder JA, Kunkel L, Wang Z, et al. Carfilzomib in multiple myeloma patients with renal impairment: Pharmacokinetics and safety. Leukemia. 2013;27:1707-1714","DOI":"10.1038\/leu.2013.29"},{"key":"ref=99","doi-asserted-by":"crossref","unstructured":"Dimopoulos M, Siegel D, White DJ, Boccia R, Iskander KS, Yang Z, et al. Carfilzomib vs bortezomib in patients with multiple myeloma and renal failure: A subgroup analysis of ENDEAVOR. Blood. 2019;133:147-155","DOI":"10.1182\/blood-2018-06-860015"},{"key":"ref=100","doi-asserted-by":"crossref","unstructured":"Zhou Y, Ma X, Yu H, Hu C, Fan L, Ran X. Carfilzomib\/pomalidomide single-agent or in combination with other agents for the management of relapsed\/refractory multiple myeloma: A meta-analysis of 37 trials. Oncotarget. 2017;8:39805-39817","DOI":"10.18632\/oncotarget.10768"},{"key":"ref=101","doi-asserted-by":"crossref","unstructured":"Tzogani K, Florez B, Markey G, Caleno M, Olimpieri OM, Melchiorri D, et al. European Medicines Agency review of ixazomib (Ninlaro) for the treatment of adult patients with multiple myeloma who have received at least one prior therapy. ESMO Open. 2019;4:e000570","DOI":"10.1136\/esmoopen-2019-000570"},{"key":"ref=102","doi-asserted-by":"crossref","unstructured":"Gupta N, Hanley MJ, Harvey RD, Badros A, Lipe B, Kukreti V, et al. A pharmacokinetics and safety phase 1\/1b study of oral ixazomib in patients with multiple myeloma and severe renal impairment or end-stage renal disease requiring haemodialysis. British Journal of Haematology. 2016;174:748-759","DOI":"10.1111\/bjh.14125"},{"key":"ref=103","doi-asserted-by":"crossref","unstructured":"Derudas D, Capraro F, Martinelli G, Cerchione C. Old and new generation immunomodulatory drugs in multiple myeloma. Panminerva Medica. 2020;62(4):207-219","DOI":"10.23736\/S0031-0808.20.04125-7"},{"key":"ref=104","doi-asserted-by":"crossref","unstructured":"Eriksson T, Hoglund P, Turesson I, Waage A, Don BR, Vu J, et al. Pharmacokinetics of thalidomide in patients with impaired renal function and while on and off dialysis. The Journal of Pharmacy and Pharmacology. 2003;55:1701-1706","DOI":"10.1211\/0022357022241"},{"key":"ref=105","doi-asserted-by":"crossref","unstructured":"Tosi P, Zamagni E, Cellini C, Cangini D, Racchetti P, Tura S, et al. M. Thalidomide alone or in combination with dexamethasone in patients with advanced, relapsed or refractory multiple myeloma and renal failure. European Journal of Haematology. 2004;73:98-103","DOI":"10.1111\/j.1600-0609.2004.00272.x"},{"key":"ref=106","unstructured":"Kreiniz N, Khateeb A, Gino-Moor S, Polliack A, Tadmor T, et al. Acute renal failure associated with lenalidomide treatment in multiple myeloma: A rare occurrence? Anticancer Research. 2016;36:2889-2892"},{"key":"ref=107","doi-asserted-by":"crossref","unstructured":"Mikhael J, Manola J, Dueck AC, Hayman S, Oettel K, Kanate AS, et al. Lenalidomide and dexamethasone in patients with relapsed multiple myeloma and impaired renal function: PrE1003, a PrECOG study. Blood Cancer Journal. 2018;8:86","DOI":"10.1038\/s41408-018-0110-7"},{"key":"ref=108","doi-asserted-by":"crossref","unstructured":"Oehrlein K, Langer C, Strum I, Ponisch W, Hahn-Ast C, Kuhn S, et al. Successful treatment of patients with multiple myeloma and impaired renal function with lenalidomide: Results of 4 German centers. Clinical Lymphoma, Myeloma & Leukemia. 2012;12:191-196","DOI":"10.1016\/j.clml.2012.01.001"},{"key":"ref=109","doi-asserted-by":"crossref","unstructured":"Fouquet G, Bories C, Guidez S, Renaud L, Herbaux C, Javed S, et al. Pomalidomide for multiple myeloma. Expert Review of Hematology. 2014;7:719-731","DOI":"10.1586\/17474086.2014.966074"},{"key":"ref=110","doi-asserted-by":"crossref","unstructured":"Dimopoulos M, Weisel K, van de Donk NWCJ, Ramasamy K, Gamberi B, Streetly M, et al. Pomalidomide plus low-dose dexamethasone in patients with relapsed\/refractory multiple myeloma and renal impairment: Results from a Phase II Trial. Journal of Clinical Oncology. 2018;36:2035-2043","DOI":"10.1200\/JCO.2017.76.1742"},{"key":"ref=111","doi-asserted-by":"crossref","unstructured":"De Weers M, Tai YT, van der Veer MS, Bakker JM, Vink T, Jacobs DCH, et al. Daratumumab, a novel therapeutic human CD38 monoclonal antibody, induces killing of multiple myeloma and other hematological tumors. Journal of Immunology. 2011;186:1840-1848","DOI":"10.4049\/jimmunol.1003032"},{"key":"ref=112","doi-asserted-by":"crossref","unstructured":"Kuzume A, Tabata R, Terao T, Tsushima T, Miura D, Narita K, et al. Safety and efficacy of daratumumab in patients with multiple myeloma and severe renal failure. British Journal of Haematology. 2021;193(4):e33-e36","DOI":"10.1111\/bjh.17412"},{"key":"ref=113","doi-asserted-by":"crossref","unstructured":"Kitadate A, Kobayashi H, Abe Y, Narita K, Miura D, Takeuchi M, et al. Pre-treatment CD38-positive regulatory T cells affect the durable response to daratumumab in relapsed\/refractory multiple myeloma patients. Haematologica. 2020;105:e37-e40","DOI":"10.3324\/haematol.2019.219683"},{"key":"ref=114","doi-asserted-by":"crossref","unstructured":"Kastritis E et al. Daratumumab with dexamethasone in patients with relapsed\/refractory multiple myeloma and severe renal impairment: Results on efficacy and safety of the phase 2 dare study. Blood. 2020;136(Suppl. S1):48-49","DOI":"10.1182\/blood-2020-140322"},{"key":"ref=115","doi-asserted-by":"crossref","unstructured":"Dimopoulos MA et al. Isatuximab plus pomalidomide and dexamethasone in relapsed\/refractory multiple myeloma patients with renal impairment: ICARIA-MM subgroup analysis. Leukemia. 2021;35:562-572","DOI":"10.1038\/s41375-020-0868-z"},{"key":"ref=116","doi-asserted-by":"crossref","unstructured":"Hsi ED et al. CS1, a potential new therapeutic antibody target for the treatment of multiple myeloma. Clinical Cancer Research. 2008;14:2775-2784","DOI":"10.1158\/1078-0432.CCR-07-4246"},{"key":"ref=117","doi-asserted-by":"crossref","unstructured":"Berdeja J et al. Pharmacokinetics and safety of elotuzumab combined with lenalidomide and dexamethasone in patients with multiple myeloma and various levels of renal impairment: Results of a Phase Ib study. Clinical Lymphoma, Myeloma & Leukemia. 2016;16:129-138","DOI":"10.1016\/j.clml.2015.12.007"},{"key":"ref=118","doi-asserted-by":"crossref","unstructured":"Tai Y-T et al. Novel anti\u2013B-cell maturation antigen antibody-drug conjugate (GSK2857916) selectively induces killing of multiple myeloma. Blood. 2014;123:3128-3138","DOI":"10.1182\/blood-2013-10-535088"},{"key":"ref=119","doi-asserted-by":"crossref","unstructured":"Lonial S et al. Belantamab mafodotin for relapsed or refractory multiple myeloma (DREAMM-2): A two-arm, randomised, open-label, phase 2 study. The Lancet Oncology. 2020;21:207-221","DOI":"10.1016\/S1470-2045(19)30788-0"},{"key":"ref=120","doi-asserted-by":"crossref","unstructured":"Osborne MJ et al. The eukaryotic translation initiation factor eIF4E in the nucleus: Taking the road less traveled. Immunological Reviews. 2015;263:210-223","DOI":"10.1111\/imr.12240"},{"key":"ref=121","doi-asserted-by":"crossref","unstructured":"Bahlis NJ et al. Selinexor plus low-dose bortezomib and dexamethasone for patients with relapsed or refractory multiple myeloma. Blood. 2018;132:2546-2554","DOI":"10.1182\/blood-2018-06-858852"},{"key":"ref=122","doi-asserted-by":"crossref","unstructured":"Rodr\u00edguez-Lobato LG, Ganzetti M, Fern\u00e1ndez de Larrea C, Hudecek M, Einsele H, Danhof S. CAR T-cells in multiple myeloma: State of the art and future directions. Frontiers in Oncologia. 2020;10:1243","DOI":"10.3389\/fonc.2020.01243"},{"key":"ref=123","doi-asserted-by":"crossref","unstructured":"Bruno B, W\u00e4sch R, Engelhardt M, Gay F, Giaccone L, D'Agostino M, et al. European Myeloma Network perspective on CAR T-cell therapies for multiple myeloma. Haematologica. 2021;106(8):2054-2065","DOI":"10.3324\/haematol.2020.276402"},{"key":"ref=124","doi-asserted-by":"crossref","unstructured":"Yang Q, Li X, Zhang F, Yang Q, Zhou W, Liu J. Efficacy and safety of CAR-T therapy for relapse or refractory multiple myeloma: A systematic review and meta-analysis. International Journal of Medical Sciences. 2021;18(8):1786-1797","DOI":"10.7150\/ijms.46811"},{"key":"ref=125","doi-asserted-by":"crossref","unstructured":"Moreau P, Touzeau C. T-cell redirecting bispecific antibodies in multiple myeloma: A revolution? Blood. 2022. Apr 11:blood.2021014611. [In press]","DOI":"10.1182\/blood.2021014611"},{"key":"ref=126","doi-asserted-by":"crossref","unstructured":"Swan D, Routledge D, Harrison S. The evolving status of immunotherapies in multiple myeloma: The future role of bispecific antibodies. British Journal of Haematology. 2022;196(3):488-506. Epub 2021 Sep 1","DOI":"10.1111\/bjh.17805"},{"key":"ref=127","doi-asserted-by":"crossref","unstructured":"Lancman G, Sastow DL, Cho HJ, Jagannath S, Madduri D, Parekh SS, et al. Bispecific antibodies in multiple myeloma: Present and future. Blood Cancer Discovery. 2021;2(5):423-433","DOI":"10.1158\/2643-3230.BCD-21-0028"},{"key":"ref=128","doi-asserted-by":"crossref","unstructured":"Kumar SK, Harrison SJ, Cavo M, de la Rubia J, Popat R, Gasparetto C, et al. Venetoclax or placebo in combination with bortezomib and dexamethasone in patients with relapsed or refractory multiple myeloma (BELLINI): A randomised, double-blind, multicentre, phase 3 trial. The Lancet Oncology. 2020;21(12):1630-1642","DOI":"10.1016\/S1470-2045(20)30525-8"},{"key":"ref=129","doi-asserted-by":"crossref","unstructured":"Boccon-Gibod C, Talbot A, Le Bras F, Frenzel L, Royer B, Harel S, et al. Carfilzomib, venetoclax and dexamethasone for relapsed\/refractory multiple myeloma. British Journal of Haematology. 2020;189(3):e73-e76","DOI":"10.1111\/bjh.16483"},{"key":"ref=130","doi-asserted-by":"crossref","unstructured":"Kaufman JL, Gasparetto C, Schjesvold FH, Moreau P, Touzeau C, Facon T, et al. Targeting BCL-2 with venetoclax and dexamethasone in patients with relapsed\/refractory t(11;14) multiple myeloma. American Journal of Hematology. 2021;96(4):418-427","DOI":"10.1002\/ajh.26083"},{"key":"ref=131","doi-asserted-by":"crossref","unstructured":"D'Agostino M, Salvini M, Palumbo A, Larocca A, Gay F. Novel investigational drugs active as single agents in multiple myeloma. Expert Opinion on Investigational Drugs. 2017;26(6):699-711","DOI":"10.1080\/13543784.2017.1324571"},{"key":"ref=132","doi-asserted-by":"crossref","unstructured":"Morabito F, Tripepi G, Martino EA, Vigna E, Mendicino F, Morabito L, et al. Spotlight on melphalan flufenamide: An up-and-coming therapy for the treatment of myeloma. Drug Design, Development and Therapy. 2021;15:2969-2978","DOI":"10.2147\/DDDT.S295215"},{"key":"ref=133","doi-asserted-by":"crossref","unstructured":"Richardson PG, Oriol A, Larocca A, Blad\u00e9 J, Cavo M, Rodriguez-Otero P, et al. HORIZON (OP-106) Investigators. Melflufen and dexamethasone in heavily pretreated relapsed and refractory multiple myeloma. Journal of Clinical Oncology. 2021;39(7):757-767","DOI":"10.1200\/JCO.20.02259"},{"key":"ref=134","doi-asserted-by":"crossref","unstructured":"Bjorklund CC, Kang J, Amatangelo M, Polonskaia A, Katz M, Chiu H, et al. Iberdomide (CC-220) is a potent cereblon E3 ligase modulator with antitumor and immunostimulatory activities in lenalidomide- and pomalidomide-resistant multiple myeloma cells with dysregulated CRBN. Leukemia. 2020;34(4):1197-1201","DOI":"10.1038\/s41375-019-0620-8"},{"key":"ref=135","doi-asserted-by":"crossref","unstructured":"Thakurta A, Pierceall WE, Amatangelo MD, Flynt E, Agarwal A. Developing next generation immunomodulatory drugs and their combination in multiple myeloma. Oncotarget. 2021;12(15):1555-1563","DOI":"10.18632\/oncotarget.27973"},{"key":"ref=136","doi-asserted-by":"crossref","unstructured":"Sweiss K, Vemu B, Hofmeister CC, Wenzler E, Calip GS, Galvin JP, et al. Development of a method for clinical pharmacokinetic testing to allow for targeted Melphalan dosing in multiple myeloma patients undergoing autologous transplant. British Journal of Clinical Pharmacology. 2020","DOI":"10.1111\/bcp.14308"},{"key":"ref=137","doi-asserted-by":"crossref","unstructured":"Al Hamed R, Bazarbachi AH, Malard F, Harousseau JL, Mohty M. Current status of autologous stem cell transplantation for multiple myeloma. Blood Cancer Journal. 2019;9(4):44","DOI":"10.1038\/s41408-019-0205-9"},{"key":"ref=138","doi-asserted-by":"crossref","unstructured":"Poczta A, Rogalska A, Marczak A. Treatment of multiple myeloma and the role of melphalan in the era of modern therapies-current research and clinical approaches. Journal of Clinical Medicine. 2021;10(9):1841","DOI":"10.3390\/jcm10091841"},{"key":"ref=139","doi-asserted-by":"crossref","unstructured":"Zhong H, Xie X, Xu G. Autologous stem cell transplantation in multiple myeloma with renal failure: Friend or Foe? Stem Cells International. 2019;2019:9401717","DOI":"10.1155\/2019\/9401717"},{"key":"ref=140","doi-asserted-by":"crossref","unstructured":"Nath CE, Trotman J, Tiley C, Presgrave P, Joshua D, Kerridge I, et al. High melphalan exposure is associated with improved overall survival in myeloma patients receiving high dose melphalan and autologous transplantation. British Journal of Clinical Pharmacology. 2016;82(1):149-159","DOI":"10.1111\/bcp.12906"},{"key":"ref=141","doi-asserted-by":"crossref","unstructured":"Wanchoo R, Abudayyeh A, Doshi M, Edeani A, Glezerman IG, Monga D, et al. Renal toxicities of novel agents used for treatment of multiple myeloma. Clinical Journal of the American Society of Nephrology. 2017;12(1):176-189","DOI":"10.2215\/CJN.06100616"},{"key":"ref=142","doi-asserted-by":"crossref","unstructured":"Sweiss K, Patel S, Culos K, Oh A, Rondelli D, Patel P. Melphalan 200\u2009mg\/m2 in patients with renal impairment is associated with increased short-term toxicity but improved response and longer treatment-free survival. Bone Marrow Transplantation. 2016;51(10):1337-1341","DOI":"10.1038\/bmt.2016.136"},{"key":"ref=143","doi-asserted-by":"crossref","unstructured":"Waszcuk-Gaida A et al. Safety and efficacy of autologous stem cell transplantation in dialysis-dependent myeloma patients\u2014The diadem study from the chronic malignancies working party of the EBMT. Blood. 2019;134(Suppl_1):4574","DOI":"10.1182\/blood-2019-127238"},{"key":"ref=144","doi-asserted-by":"crossref","unstructured":"Knudsen LM, Nielsen B, Gimsing P, Geisler C. Autologous stem cell transplantation in multiple myeloma: Outcome in patients with renal failure. European Journal of Haematology. 2005;75(1):27-33","DOI":"10.1111\/j.1600-0609.2005.00446.x"},{"key":"ref=145","doi-asserted-by":"crossref","unstructured":"Hamadani M, Kochuparambil ST, Osman S, Cumpston A, Leadmon S, Bunner P, et al. Intermediate-dose versus low-dose cyclophosphamide and granulocyte colony-stimulating factor for peripheral blood stem cell mobilization in patients with multiple myeloma treated with novel induction therapies. Biology of Blood and Marrow Transplantation. 2012;18(7):1128-1135","DOI":"10.1016\/j.bbmt.2012.01.005"},{"key":"ref=146","doi-asserted-by":"crossref","unstructured":"Tuchman SA, Bacon WA, Huang LW, Long G, Rizzieri D, Horwitz M, et al. Cyclophosphamide-based hematopoietic stem cell mobilization before autologous stem cell transplantation in newly diagnosed multiple myeloma. Journal of Clinical Apheresis. 2015;30(3):176-182","DOI":"10.1002\/jca.21360"},{"key":"ref=147","doi-asserted-by":"crossref","unstructured":"Al-Anazi KA. Autologous hematopoietic stem cell transplantation for multiple myeloma without cryopreservation. Bone Marrow Research. 2012;2012:917361","DOI":"10.1155\/2012\/917361"},{"key":"ref=148","doi-asserted-by":"crossref","unstructured":"Lin TL, Wang PN, Kuo MC, Hung YH, Chang H, Tang TC. Cyclophosphamide plus granulocyte-colony stimulating factor for hematopoietic stem cell mobilization in patients with multiple myeloma. Journal of Clinical Apheresis. 2016;31(5):423-428","DOI":"10.1002\/jca.21421"},{"key":"ref=149","doi-asserted-by":"crossref","unstructured":"Russell N, Douglas K, Ho AD, Mohty M, Carlson K, Ossenkoppele GJ, et al. Plerixafor and granulocyte colony-stimulating factor for first-line steady-state autologous peripheral blood stem cell mobilization in lymphoma and multiple myeloma: Results of the prospective PREDICT trial. Haematologica. 2013;98(2):172-178","DOI":"10.3324\/haematol.2012.071456"},{"key":"ref=150","doi-asserted-by":"crossref","unstructured":"Nademanee AP, DiPersio JF, Maziarz RT, Stadtmauer EA, Micallef IN, Stiff PJ, et al. Plerixafor plus granulocyte colony-stimulating factor versus placebo plus granulocyte colony-stimulating factor for mobilization of CD34(+) hematopoietic stem cells in patients with multiple myeloma and low peripheral blood CD34(+) cell count: Results of a subset analysis of a randomized trial. Biology of Blood and Marrow Transplantation. 2012;18(10):1564-1567","DOI":"10.1016\/j.bbmt.2012.05.017"},{"key":"ref=151","doi-asserted-by":"crossref","unstructured":"Waldmann TA, Strober W, Mogielnicki RP. The renal handling of low molecular weight proteins. II. Disorders of serum protein catabolism in patients with tubular proteinuria, the nephrotic syndrome, or uremia. The Journal of Clinical Investigation. 1972;51:2162-2174","DOI":"10.1172\/JCI107023"},{"key":"ref=152","doi-asserted-by":"crossref","unstructured":"Miettinen TA et al. Effect of impaired hepatic and renal function on Bence Jones protein catabolism in human subjects. Clinica Chimica Acta. 1967;18:395-407","DOI":"10.1016\/0009-8981(67)90036-8"},{"key":"ref=153","doi-asserted-by":"crossref","unstructured":"Hutchison CA, Harding S, Hewins P, Mead GP, Townsend J, Bradwell AR, et al. Quantitative assessment of serum and urinary polyclonal free light chains in patients with chronic kidney disease. Clinical Journal of the American Society of Nephrology. 2008;3:1684-1690","DOI":"10.2215\/CJN.02290508"},{"key":"ref=154","doi-asserted-by":"crossref","unstructured":"Hutchison CA, Cockwell P, Harding S, Mead GP, Bradwell AR, et al. Quantitative assessment of serum and urinary polyclonal free light chains in patients with type II diabetes: An early marker of diabetic kidney disease? Expert Opinion on Therapeutic Targets. 2008;12:667-676","DOI":"10.1517\/14728222.12.6.667"},{"key":"ref=155","doi-asserted-by":"crossref","unstructured":"Hutchison CA, Cockwell P, Reid S, Chandler K, Mead GP, Harrison J, et al. Efficient removal of immunoglobulin free light chains by hemodialysis for multiple myeloma: In vitro and in vivo studies. Journal of the American Society of Nephrology. 2007;18:886-895","DOI":"10.1681\/ASN.2006080821"},{"key":"ref=156","doi-asserted-by":"crossref","unstructured":"Ludwig H, Adam Z, Hajek R, Greil R, Tothova E, Keil F, et al. Light chain-induced acute renal failure can be reversed by bortezomib-doxorubicin-dexamethasone in multiple myeloma: Results of a phase II study. Journal of Clinical Oncology. 2010;28:4635-4641","DOI":"10.1200\/JCO.2010.28.1238"},{"key":"ref=157","doi-asserted-by":"crossref","unstructured":"Clark WF, Stewart AK, Rock GA, Sternbach M, Sutton DM, Barrett BJ, et al. Plasma exchange when myeloma presents as acute renal failure: A randomized, controlled trial. Annals of Internal Medicine. 2005;143:777-784","DOI":"10.7326\/0003-4819-143-11-200512060-00005"},{"key":"ref=158","doi-asserted-by":"crossref","unstructured":"Burnette BL, Leung N, Rajkumar SV. Renal improvement in myeloma with bortezomib plus plasma exchange. The New England Journal of Medicine. 2011;364:2365-2366","DOI":"10.1056\/NEJMc1101834"},{"key":"ref=159","doi-asserted-by":"crossref","unstructured":"Hutchison CA, Bradwell AR, Cook M, Basnayake K, Basu S, Harding S, et al. Treatment of acute renal failure secondary to multiple myeloma with chemotherapy and extended high cut-off haemodialysis. Clinical Journal of the American Society of Nephrology. 2009;4:745-754","DOI":"10.2215\/CJN.04590908"},{"key":"ref=160","doi-asserted-by":"crossref","unstructured":"Heyne N, Denecke B, Guthoff M, Oehrlein K, Kanz L, Haring HU, et al. Extracorporeal light chain elimination: High cut-off (HCO) haemodialysis parallel to chemotherapy allows for a high proportion of renal recovery in multiple myeloma patients with dialysis-dependent acute kidney injury. Annals of Hematology. 2012;91:729-735","DOI":"10.1007\/s00277-011-1383-0"},{"key":"ref=161","doi-asserted-by":"crossref","unstructured":"Zannetti BA, Zamagni E, Santostefano M, De Sanctis LB, Tacchetti P, Mancini E, et al. Bortezomib-based therapy combined with high cut-off haemodialysis is highly effective in newly diagnosed multiple myeloma patients with severe renal impairment. American Journal of Hematology. 2015;90:647-652","DOI":"10.1002\/ajh.24035"},{"key":"ref=162","doi-asserted-by":"crossref","unstructured":"Curti A, Schwartz A, Trachsler J, Tomonaga Y, Ambuhl PM. Therapeutic efficacy and cost effectiveness of high cut-off dialyzers compared to conventional dialysis in patients with cast nephropathy. PLoS ONE. 2016","DOI":"10.1371\/journal.pone.0159942"},{"key":"ref=163","doi-asserted-by":"crossref","unstructured":"Morabito F, Gentile M, Ciolli S, Petrucci MT, Galimberti S, Mele G, et al. Safety and efficacy of bortezomib-based regimens for multiple myeloma patients with renal impairment: A retrospective study of Italian Myeloma Network GIMEMA. European Journal of Haematology. 2010;84:223-228","DOI":"10.1111\/j.1600-0609.2009.01385.x"},{"key":"ref=164","doi-asserted-by":"crossref","unstructured":"Hutchison CA, Cockwell P, Moroz V, Bradwell AR, Fifer L, Gillmore JD, et al. High cutoff versus high-flux haemodialysis for myeloma cast nephropathy in patients receiving bortezomib-based chemotherapy (EuLITE): A phase 2 randomised controlled trial. Lancet Haematology. 2019;6:e217-e228","DOI":"10.1016\/S2352-3026(19)30014-6"},{"key":"ref=165","doi-asserted-by":"crossref","unstructured":"Arimura A, Li M, Batuman V. Potential protective action of pituitary adenylate cyclase-activating polypeptide (PACAP38) on in vitro and in vivo models of myeloma kidney injury. Blood. 2006;107(2):661-668","DOI":"10.1182\/blood-2005-03-1186"},{"key":"ref=166","doi-asserted-by":"crossref","unstructured":"Sharland A, Snowdon L, Joshua DE, Gibson J, Tiller DJ. Hemodialysis: An appropriate therapy in myeloma-induced renal failure. American Journal of Kidney Diseases. 1997;30:786-792","DOI":"10.1016\/S0272-6386(97)90083-4"}],"container-title":["Recent Updates on Multiple Myeloma"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/www.intechopen.com\/download\/pdf\/82258","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,3,15]],"date-time":"2023-03-15T14:51:09Z","timestamp":1678891869000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.intechopen.com\/chapters\/82258"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,3,15]]},"ISBN":["9781803560922","9781803560939"],"references-count":166,"URL":"https:\/\/doi.org\/10.5772\/intechopen.105444","relation":{},"subject":[],"published":{"date-parts":[[2023,3,15]]}}}